Cargando…

Fractioned Dose Regimen of Sunitinib for Patients with Gastrointestinal Stromal Tumor: A Pharmacokinetic and Treatment Efficacy Study()

AIM: Sunitinib has shown benefit in patients with imatinib (IM)–resistant gastrointestinal stromal tumor (GIST). However, its advantages are somewhat diminished because of associated toxicities. Herein, we clarify the efficacy and safety of fractioned dose regimen of sunitinib by a pharmacokinetic a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chen, Yen-Yang, Yeh, Chun-Nan, Cheng, Chi-Tung, Wu, Chao-En, Chiang, Kun-Chun, Chen, Tsung-Wen, Wang, Chih-Chi, Chen, Jen-Shi, Yeh, Ta-Sen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Neoplasia Press 2014
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4225693/ https://www.ncbi.nlm.nih.gov/pubmed/25389456 http://dx.doi.org/10.1016/j.tranon.2014.08.004

Ejemplares similares

Regorafenib treatment outcome for Taiwanese patients with metastatic gastrointestinal stromal tumors after failure of imatinib and sunitinib: A prospective, non-randomized, single-center study
por: Hu, Chia-Hsiang, et al.
Publicado: (2020)

Role of PLK1 signaling pathway genes in gastrointestinal stromal tumors
por: Chen, Jen-Shi, et al.
Publicado: (2018)

Prospective Evaluation of Neoadjuvant Imatinib Use in Locally Advanced Gastrointestinal Stromal Tumors: Emphasis on the Optimal Duration of Neoadjuvant Imatinib Use, Safety, and Oncological Outcome
por: Wang, Shang-Yu, et al.
Publicado: (2019)

Imatinib dose escalation versus sunitinib as a second-line treatment against advanced gastrointestinal stromal tumors: A nationwide population-based cohort study
por: Hsu, Jun-Te, et al.
Publicado: (2017)

Feasibility and Timing of Cytoreduction Surgery in Advanced (Metastatic or Recurrent) Gastrointestinal Stromal Tumors During the Era of Imatinib
por: Chang, Shih-Chun, et al.
Publicado: (2016)

Identification of aurora kinase A as an unfavorable prognostic factor and potential treatment target for metastatic gastrointestinal stromal tumors
por: Yeh, Chun-Nan, et al.
Publicado: (2014)

A Nomogram Predicting Progression Free Survival in Patients with Gastrointestinal Stromal Tumor Receiving Sunitinib: Incorporating Pre-Treatment and Post-Treatment Parameters
por: Chang, Yau-Ren, et al.
Publicado: (2021)

Extrapolation of pharmacokinetics and pharmacodynamics of sunitinib in children with gastrointestinal stromal tumors
por: Khosravan, Reza, et al.
Publicado: (2021)

Prediction of Gastric Gastrointestinal Stromal Tumors before Operation: A Retrospective Analysis of Gastric Subepithelial Tumors
por: Lin, Yu-Ning, et al.
Publicado: (2022)

Systemic Therapy for Gastrointestinal Stromal Tumor: Current Standards and Emerging Challenges
por: Huang, Wen-Kuan, et al.
Publicado: (2022)

Cytoreductive Surgery may be beneficial for highly selected patients with Metastatic Gastrointestinal Stromal Tumors receiving Regorafenib facing Local Progression: A Case Controlled Study
por: Yeh, Chun-Nan, et al.
Publicado: (2021)

Targeted ultra-deep sequencing unveils a lack of driver-gene mutations linking non-hereditary gastrointestinal stromal tumors and highly prevalent second primary malignancies: random or nonrandom, that is the question
por: Lai, Bo-Ru, et al.
Publicado: (2016)

HO-1 is a favorable prognostic factor for HBV-HCC patients who underwent hepatectomy
por: Yeh, Chun-Nan, et al.
Publicado: (2018)

Peritumoral SPARC expression and patient outcome with resectable intrahepatic cholangiocarcinoma
por: Cheng, Chi-Tung, et al.
Publicado: (2015)

Sunitinib in the treatment of gastrointestinal stromal tumor: patient selection and perspectives
por: Mulet-Margalef, Nuria, et al.
Publicado: (2016)

p53 as a biomarker and potential target in gastrointestinal stromal tumors
por: Wu, Chiao-En, et al.
Publicado: (2022)

Population Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib by Dosing Schedule in Patients with Advanced Renal Cell Carcinoma or Gastrointestinal Stromal Tumor
por: Khosravan, Reza, et al.
Publicado: (2016)

Compassionate Use of Ripretinib for Patients With Metastatic Gastrointestinal Stromal Tumors: Taiwan and Hong Kong Experience
por: Lin, Li-Ching, et al.
Publicado: (2022)

Pneumatosis Cystoides Intestinalis Secondary to Sunitinib Treatment for Gastrointestinal Stromal Tumor
por: Asahi, Yoh, et al.
Publicado: (2018)

Clinical Diagnosis of Gastrointestinal Stromal Tumor (GIST): From the Molecular Genetic Point of View
por: Wu, Chiao-En, et al.
Publicado: (2019)

A phase II trial of regorafenib in patients with metastatic and/or a unresectable gastrointestinal stromal tumor harboring secondary mutations of exon 17
por: Yeh, Chun-Nan, et al.
Publicado: (2017)

Population Pharmacokinetics of Sunitinib and its Active Metabolite SU012662 in Pediatric Patients with Gastrointestinal Stromal Tumors or Other Solid Tumors
por: Wang, Erjian, et al.
Publicado: (2021)

Corrigendum: Compassionate use of ripretinib for patients with metastatic gastrointestinal stromal tumors: Taiwan and Hong Kong experience
por: Lin, Li-Ching, et al.
Publicado: (2022)

Clinical effect of a positive surgical margin after hepatectomy on survival of patients with intrahepatic cholangiocarcinoma
por: Yeh, Chun-Nan, et al.
Publicado: (2014)

Bowel perforation associated sunitinib therapy for recurred gastric gastrointestinal stromal tumor
por: Kim, Hyo-Sin, et al.
Publicado: (2014)

Prognostic Value of the Preoperative Neutrophil to Lymphocyte Ratio in Resectable Gastric Cancer
por: Hsu, Jun-Te, et al.
Publicado: (2015)

Lipocalin 2 (LCN2) is a promising target for cholangiocarcinoma treatment and bile LCN2 level is a potential cholangiocarcinoma diagnostic marker
por: Chiang, Kun-Chun, et al.
Publicado: (2016)

Surgery after treatment with imatinib and/or sunitinib in patients with metastasized gastrointestinal stromal tumors: is it worthwhile?
por: Tielen, Ronald, et al.
Publicado: (2012)

Effect of Synchronous Versus Sequential Regimens on the Pharmacokinetics and Biodistribution of Regorafenib with Irradiation
por: Tsai, Tung-Hu, et al.
Publicado: (2021)

Non‐small cell lung cancer with gastric metastasis and repeated gastrointestinal bleeding: A rare case report and literature review
por: Shih‐Chun, Chang, et al.
Publicado: (2021)

Clinical practice guidelines for patients with gastrointestinal stromal tumor in Taiwan
por: Yeh, Chun-Nan, et al.
Publicado: (2012)

Aspartate and Acetate Fuel Gastrointestinal Stromal Tumors Beyond the Warburg Effect
por: Lai, Ying-Chieh, et al.
Publicado: (2022)

Identification of SPHK1 as a therapeutic target and marker of poor prognosis in cholangiocarcinoma
por: Chen, Ming-Huang, et al.
Publicado: (2015)

Impact of Overlapping Functional Gastrointestinal Disorders on the Presentation and Quality of Life of Patients with Erosive Esophagitis and Nonerosive Reflux Disease
por: Lee, Shou-Wu, et al.
Publicado: (2015)

Antitumor activity of the combination of an HSP90 inhibitor and a PI3K/mTOR dual inhibitor against cholangiocarcinoma
por: Chen, Ming-Huang, et al.
Publicado: (2014)

Alternative schedules or integration strategies to maximise treatment duration with sunitinib in patients with gastrointestinal stromal tumours
por: SAPONARA, MARISTELLA, et al.
Publicado: (2014)

Impact of Rechallenge with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumor after Failure of Imatinib and Sunitinib
por: Sawaki, Akira, et al.
Publicado: (2014)

Sunitinib Treatment for Multiple Brain Metastases from Jejunal Gastrointestinal Stromal Tumor: Case Report
por: TAKEUCHI, Hayato, et al.
Publicado: (2014)

Response to sunitinib of a gastrointestinal stromal tumor with a rare exon 12 PDGFRA mutation
por: Brohl, Andrew S., et al.
Publicado: (2015)

Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib
por: Vincenzi, Bruno, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_9bc24mult9er4gruuvujg2tb30